Loading viewer...
annual_report
Format: PDF annual_report
ACADIA Pharmaceuticals' 2023 annual report highlights record revenues of $726.4 million driven by successful commercial launches of NUPLAZID and DAYBUE, first-in-class treatments for Parkinson's disease psychosis and Rett syndrome respectively. The company achieved cash flow positivity and advanced a robust pipeline including Phase 3 studies for Prader-Willi syndrome and Alzheimer's disease psychosis.
annual_report
Khazanah
CPI Aerostructures 2008 Annual Report
annual_reportannual_report
28 Pages
CPI Aerostructures
presentation
Siemens
annual_report
CarMax